Physiologically based pharmacokinetic (PBPK) models provide a framework useful for generating credible human pharmacokinetic predictions from data available at the earliest, preclinical stages of pharmaceutical research. With this approach, the pharmacokinetic implications of in vitro data are contextualized via scaling according to independent physiological information. However, in many cases these models also require model-based estimation of additional empirical scaling factors (SFs) in order to accurately recapitulate known human pharmacokinetic behavior. While this practice clearly improves data characterization, the introduction of empirically derived SFs may belie the extrapolative power commonly attributed to PBPK. This is particularly true when such SFs are compound dependent and/or when there are issues with regard to identifiability. As such, when empirically-derived SFs are necessary, a critical evaluation of parameter estimation and model structure are prudent. In this study, we applied a global optimization method to support model-based estimation of a single set of empirical SFs from intravenous clinical data on seven OATP substrates within the context of a previously published PBPK model as well as a revised PBPK model. The revised model with experimentally measured unbound fraction in liver, permeability between liver compartments, and permeability limited distribution to selected tissues improved data characterization. We utilized large-sample approximation and resampling approaches to estimate confidence intervals for the revised model in support of forward predictions that reflect the derived uncertainty. This work illustrates an objective approach to estimating empirically-derived SFs, systematically refining PBPK model performance and conveying the associated confidence in subsequent forward predictions.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45–73. doi:10.1146/annurev-pharmtox-010510-100540
Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S (2011) Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 50(5):331–347. doi:10.2165/11539680-000000000-00000
Jones HM, Parrott N, Jorga K, Lave T (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45(5):511–542. doi:10.2165/00003088-200645050-00006
De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA (2007) Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35(10):1766–1780. doi:10.1124/dmd.107.015644
Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6(2):140–148. doi:10.1038/nrd2173
Poirier A, Cascais AC, Funk C, Lave T (2009) Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 36(6):585–611. doi:10.1007/s10928-009-9139-3
Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328(2):652–662. doi:10.1124/jpet.108.146647
Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y (2010) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38(2):215–222. doi:10.1124/dmd.109.030254
Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40(5):1007–1017. doi:10.1124/dmd.111.042994
Tsamandouras N, Rostami-Hodjegan A, Aarons L (2013) Combining the “bottom-up” and “top-down” approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. doi:10.1111/bcp.12234
Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238–1257. doi:10.1002/jps.20502
Vanlier J, Tiemann CA, Hilbers PA, van Riel NA (2012) An integrated strategy for prediction uncertainty analysis. Bioinformatics 28(8):1130–1135. doi:10.1093/bioinformatics/bts088
Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86. doi:10.1007/s10928-011-9232-2
Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23(8):327–338. doi:10.1002/bdd.325
Seber GAF, Wild CJ (2003) Nonlinear regression., Wiley series in probability and statisticsWiley-Interscience, Hoboken
Thai HT, Mentre F, Holford NH, Veyrat-Follet C, Comets E (2013) A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models. Pharm Stat 12(3):129–140. doi:10.1002/pst.1561
Poirier A, Cascais AC, Funk C, Lave T (2009) Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers 6(11):1975–1987. doi:10.1002/cbdv.200900116
Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V (2013) Mechanistic modeling to predict the transporter- and enzyme-mediated drug–drug interactions of repaglinide. Pharm Res 30(4):1188–1199. doi:10.1007/s11095-012-0956-5
Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53(1):73–87. doi:10.1007/s40262-013-0097-y
Tomita Y, Maeda K, Sugiyama Y (2013) Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther 94(1):37–51. doi:10.1038/clpt.2012.221
Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158(3):693–705. doi:10.1111/j.1476-5381.2009.00430.x
Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36(10):2014–2023. doi:10.1124/dmd.108.021410
About this article
Cite this article
Li, R., Barton, H.A., Yates, P.D. et al. A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J Pharmacokinet Pharmacodyn 41, 197–209 (2014). https://doi.org/10.1007/s10928-014-9357-1
- Scaling factor
- Global optimization
- Sandwich cultured human hepatocytes